Ipamorelin vs GHRP-6: the short answer
Ipamorelin and GHRP-6 both activate the growth hormone secretagogue receptor, GHS-R1a, and both release growth hormone at comparable potency in animal models. The difference that decides which one a protocol should use is cortisol. GHRP-6 raises ACTH and cortisol alongside GH; ipamorelin does not, even at doses 200 times its own GH-releasing threshold.
| Metric | Ipamorelin | GHRP-6 |
|---|---|---|
| Structure | Pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Receptor | GHS-R1a | GHS-R1a |
| First described | 1998, Novo Nordisk (Raun et al.) | 1984, Tulane University (Bowers et al.) |
| GH potency in swine, ED50 | 2.3 nmol/kg | 3.9 nmol/kg |
| ACTH and cortisol at GH-releasing doses | No significant rise | Significant rise |
| FSH, LH, prolactin, TSH | Unaffected | Unaffected |
| Human data available | Pharmacokinetic study, healthy male volunteers | Mechanistic studies, healthy men and obese adults |
For research designs that need GH release without a cortisol confound, ipamorelin has the published selectivity data. For work centered on GHS-R1a pharmacology broadly, including the receptor's link to ghrelin, GHRP-6 has the longer track record and more mechanistic human studies behind it.
What each compound is
GHRP-6 is a synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, first described by Bowers et al. at Tulane University in 1984 (Bowers et al., Endocrinology, 114(5):1537, 1984). The paper tested it across rats, monkeys, lambs, calves, and chicks, and found it triggered growth hormone release without a matching change in LH, FSH, TSH, or prolactin. That hormone-specific profile is what made it worth pursuing as a research tool, fifteen years before anyone had identified the receptor it worked on.
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed at Novo Nordisk from the GHRP-1 family by deleting the central Ala-Trp dipeptide. Raun et al. described it in 1998 as the first selective growth hormone secretagogue, in European Journal of Endocrinology (Raun et al., Eur J Endocrinol, 139(5):552, 1998).
Both compounds act on GHS-R1a, a G-protein coupled receptor expressed on pituitary somatotrophs and on neurons in the hypothalamic arcuate nucleus. It couples through Gq to phospholipase C, raising intracellular calcium and triggering GH exocytosis. Ghrelin, the natural hormone that activates the same receptor, was not identified until 1999, fifteen years after GHRP-6 was first synthesized.
The 1998 study that separated them
The direct comparison comes from a single paper: Raun et al., 1998, testing ipamorelin against GHRP-6 and GHRP-2 across three models. In rat pituitary cells in vitro, ipamorelin had an EC50 of 1.3 nmol/l against GHRP-6's 2.2 nmol/l. In anesthetized rats in vivo, ipamorelin's ED50 was 80 nmol/kg against GHRP-6's 115 nmol/kg. In conscious swine, ipamorelin's ED50 was 2.3 nmol/kg, GHRP-6's was 3.9 nmol/kg, and GHRP-2 came in more potent still at 0.6 nmol/kg.
GH-releasing potency put all three compounds in the same range. The separation showed up elsewhere: GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol at their GH-releasing doses. Ipamorelin did not, even at doses 200 times higher than its ED50 for GH release. None of the three compounds changed FSH, LH, prolactin, or TSH.
The paper does not explain why the cortisol effect diverges between three peptides that hit the same receptor at similar potency. It reports the finding as an empirical result, not a mechanism, and no published follow-up has resolved the structural basis for it.
Human data: two separate literatures, no head-to-head trial
No published study has tested ipamorelin against GHRP-6 in human subjects directly. Each compound has its own separate human research record.
For ipamorelin, Gobburu et al. ran a pharmacokinetic-pharmacodynamic study in healthy male volunteers across five dose levels (Gobburu et al., Pharm Res, 16(9):1412, 1999). GH release peaked 0.67 hours after dosing and fell to negligible levels at every dose tested. The terminal half-life was approximately 2 hours, clearance was 0.078 L/h/kg, and volume of distribution at steady state was 0.22 L/kg. The concentration needed for half-maximal GH stimulation was 214 nmol/L.
For GHRP-6, the human literature is mechanistic rather than pharmacokinetic. Pandya et al. gave nine healthy men aged 20 to 30 a GHRH-receptor antagonist before GHRP-6 and found the GH response dropped from 33.8 to 6.2 mcg/L (Pandya et al., J Clin Endocrinol Metab, 83(4):1186, 1998), showing that GHRP-6 needs intact hypothalamic GHRH signaling to work at full strength. Cordido et al. gave GHRP-6 to obese subjects and recorded a GH peak of 15.7 mcg/L alone, rising to a range of 14 to 86 mcg/L when combined with GHRH (Cordido et al., J Clin Endocrinol Metab, 76(4):819, 1993), a result later cited as evidence that obesity blunts GH secretion at the hypothalamic level rather than at the pituitary itself.
The two literatures answer different questions. Ipamorelin's data describes dose-response and clearance in isolation. GHRP-6's data describes where in the GH axis the compound acts and how that axis behaves in a specific patient population. Neither dataset substitutes for the comparative animal data above when the question is selectivity for GH over cortisol.
What the cortisol difference means for protocol design
Cortisol is not a passive variable in most peptide research endpoints. It independently shifts muscle protein turnover, fat metabolism, and immune markers, so any endpoint measured downstream of a GHRP-6 injection carries a second variable that ipamorelin studies do not have to account for. Protocols aiming to isolate GH-axis effects from stress hormone effects have a cleaner tool available in ipamorelin.
GHRP-6 carries a second consideration beyond cortisol: because it shares GHS-R1a with ghrelin, it activates the same arcuate-nucleus neurons that drive feeding behavior in rodent models. Whether ipamorelin produces a comparable appetite effect at GH-releasing doses has not been tested directly in the published literature, and researchers should treat this as an open question rather than an assumption in either direction.
Protocols aimed specifically at GHS-R1a pharmacology, rather than at isolating GH release, still have reasons to use GHRP-6: it carries three additional decades of mechanistic data, including the diagnostic role described above. See the GHRP-6 research overview for the fuller mechanistic history.
Handling and storage for research use in Indonesia
Both peptides ship as lyophilized powder and follow the storage profile common to short synthetic peptides: stable for extended periods frozen and unreconstituted, more fragile once dissolved. In Bali, Jakarta, and other locations where ambient temperatures run 28 to 35 degrees Celsius, lyophilized vials should stay in a freezer until the moment of reconstitution, with room-temperature exposure during handling kept under 10 to 15 minutes. The lyophilized peptide storage guide covers tropical-climate handling in more detail, and the bacteriostatic water reconstitution guide walks through the reconstitution steps themselves.
Researchers calculating injection volume from a target concentration can use the dosing calculator to convert between mass, concentration, and volume. Ipamorelin is listed alongside CJC-1295 in the Zurich Biotech compound catalog, and the fuller CJC-1295 and ipamorelin research overview covers ipamorelin's pairing with GHRH analogues in more depth.
State of the evidence as of late 2026
The comparative potency and hormone-selectivity data for ipamorelin against GHRP-6 rests on one 1998 paper, tested in rat cells, anesthetized rats, and conscious swine, not in humans. That paper's central finding, that ipamorelin spares ACTH and cortisol at doses far above its GH-releasing threshold, has not been contradicted or repeated in a published human trial as of late 2026.
Both compounds remain research-use reagents. Neither has completed a Phase 3 trial for any clinical indication, and no regulatory agency has approved either for human administration.